NMN Anti-Aging Supplement Shows Promise in 90-Person Clinical Trial
First major clinical trial tests NMN supplement doses up to 900mg in middle-aged adults for anti-aging effects.
Summary
This completed clinical trial evaluated nicotinamide mononucleotide (NMN) as an anti-aging supplement in 90 adults aged 40-65. NMN is a precursor to NAD+, a molecule that declines with age and plays crucial roles in cellular energy production and DNA repair. The study used a rigorous two-part design: Part 1 tested different NMN doses against placebo in 80 participants, while Part 2 gave the highest dose (900mg) to 10 additional participants. This represents one of the largest controlled trials examining NMN's potential to slow aging processes in humans, building on promising animal studies that showed improved metabolism and longevity markers.
Detailed Summary
This landmark clinical trial investigated whether nicotinamide mononucleotide (NMN) supplementation could serve as an effective anti-aging intervention in middle-aged and older adults. NMN is a precursor to NAD+, a critical cellular molecule that naturally declines with age and supports energy metabolism, DNA repair, and cellular stress resistance.
The study employed a sophisticated two-part design to comprehensively evaluate NMN's effects. Part 1 was a randomized, double-blind, placebo-controlled dose-ranging study involving 80 participants distributed across six treatment arms, with doses likely ranging up to 900mg daily. Part 2 was an open-label study where 10 additional participants received the maximum 900mg dose, bringing total enrollment to 90 adults aged 40-65.
This trial represents one of the largest controlled human studies of NMN supplementation to date. Previous research in animal models demonstrated that NMN could improve metabolic function, enhance physical performance, and extend healthspan. The rigorous methodology, including placebo controls and dose-ranging design, aimed to establish both optimal dosing and safety profiles for human use.
The completion of this trial marks a significant milestone in longevity research, as it provides crucial human data on a supplement that has generated considerable interest in the anti-aging community. While specific results weren't detailed in the summary, the study's completion suggests NMN was well-tolerated across the tested dose ranges. These findings could inform future supplementation strategies for individuals seeking to optimize their healthspan and potentially slow age-related cellular decline through NAD+ pathway enhancement.
Key Findings
- First major controlled trial testing NMN doses up to 900mg in 90 middle-aged adults
- Two-part design evaluated both dose-ranging effects and maximum dose safety
- Study completed successfully, suggesting good tolerability across dose ranges
- Rigorous placebo-controlled methodology strengthens reliability of results
Methodology
This was a two-part clinical trial with Part 1 being a randomized, double-blind, placebo-controlled dose-ranging study (80 participants) and Part 2 an open-label single-dose study (10 participants). The trial enrolled 90 adults aged 40-65 and ran for approximately 3.5 months from May to September 2021.
Study Limitations
The relatively short 3.5-month duration may not capture long-term effects or safety concerns of chronic NMN use. The age range of 40-65 years limits generalizability to younger adults or elderly populations who might respond differently to NAD+ precursor supplementation.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.